About bsbh

This author has not yet filled in any details.
So far bsbh has created 206 blog entries.

BIO 2019-speakers

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation? Wednesday, June 5, 2019 1:45 PM - 2:45 PM BIO International Convention - Philadelphia, PA Speakers Duane Schulthess Managing Director Vital Transformation Peter Young Venture [...]

BIO 2019-speakers2019-05-14T08:29:33+00:00

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?

Wednesday, June 5, 2019
1:45 PM - 2:45 PM
BIO International Convention - Philadelphia, PA


Following Vital Transformation's research on investment success factors for biotech companies released at the European Health Forum Gastein, this session will present original research modelling the potential impact both short and long term for patients, payers, and industry for such proposals, and show how the IPI can impact access and innovation broadly. As well, our panellists will place the IPI into the context of other models currently being investigated internationally such as value based payments, managed entry agreements, and adaptive pathways.

More Info

The International Pricing Index: What will be the Impact on Patients, Outcomes, and Innovation?2019-05-14T14:38:03+00:00

US Biotech Lobby Slams EU Reference Pricing

By CARMEN PAUN 4/9/19,
© POLITICO PRO Healthcare

U.S. biotechnology lobby BIO said the Trump administration’s proposal to peg the prices of certain drugs to a basket of mostly EU reference countries would lead to a “downward spiral” that would negatively affect the development of new medicines.

US Biotech Lobby Slams EU Reference Pricing2019-04-12T13:15:12+00:00

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets

By Duane Schulthess

It’s odd that a city like Brussels managed to carve itself out a niche as one of the major political centres of the world. The medieval site of a notoriously typhus infested bog, one of the main streets in downtown, ‘Rue du Marais’, literally means, “Street of the Swamp” and the name of the city itself comes from the old Flemish word Broekzele, which roughly translates to ‘settlement in the swamp.’ So, when one talks politically of draining the swamp, at least in Brussels, it carries a literal interpretation that is often distant from the current political climate in DC.

Don’t Believe the Hype – International Reference Pricing Will Cost Far More than 1% of R&D Budgets2019-04-12T13:09:35+00:00

Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates

Podcast - Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates EUCOPE is Europe’s principal trade body for small to medium-sized biotechnology companies working in areas often targeting orphan diseases. In this podcast we're joined by Alexander Natz, EUCOPE’s Secretary General, and Delphine Roulland, Senior Manager Public [...]

Better Science, Better Health: EUCOPE Sits at Ground Zero in the IP and Orphan Drug Debates2018-12-20T15:39:35+00:00

Better Science, Better Health: Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies

Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies Many HTAs in Europe are seen as conservative and even reactionary when it comes to innovating or changing their processes. However, Amr's PhD thesis is a 300+ page ‘how to’ manual highlighting RWE best practices [...]

Better Science, Better Health: Amr Makady of ZiN, wrote the book, LITERALLY, on how to use RWE to value new therapies2018-11-30T09:28:21+00:00

Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit

Podcast - Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit In this podcast, Steve Bates, the UK BioIndustry Association's CEO, discusses both the challenges and opportunities of Brexit on the UK’s biotechnology sector, and the need for strong, vital IP supported by private investment.Steve was an advisor to [...]

Better Science, Better Health: BIA’s CEO is the hardest working man in biotech since Brexit2018-11-19T13:40:26+00:00

Investing in EU Biotech IP – What Works?

4 December 2018 - 2.00-3.00pm CET, 8.00-9.00am ET

In this webinar we:
• Highlight the results of the research
• Expand on the datapackage used
• Discuss the gap between EU and US IP productivity in healthcare
• Address the need for IP in the global biotech sector

Download Video & Slides

Investing in EU Biotech IP – What Works?2019-04-30T10:03:06+00:00

Podcast – Better Science, Better Health: The US Chamber’s Patrick Kilbride on the Rapidly Changing IP World

Podcast - Better Science, Better Health: The US Chamber's Patrick Kilbride on the Rapidly Changing IP World Patrick Kilbride is vice president of international intellectual property for the Global Innovation Policy Center (GIPC) at the U.S. Chamber of Commerce. Over the last several years, there has been a growing chorus of voices [...]

Podcast – Better Science, Better Health: The US Chamber’s Patrick Kilbride on the Rapidly Changing IP World2018-11-19T13:40:36+00:00

Better Science, Better Health – Stirring the IP Pot

Podcast - Better Science, Better Health: Stirring the IP Pot Emil Pot was one of the founders of ActoGeniX, which was successfully acquired in 2015 by Intrexon. Emil outlines the ingredients Europe needs to build a company from scratch, and leverage home-grown Intellectual Property.

Better Science, Better Health – Stirring the IP Pot2018-11-19T13:40:46+00:00